

1. Battistone M, **Pendleton R**, Milne C, Battistone ME, Sande M, Hemmer P (2001). Global Descriptive Evaluations are more responsive than global numeric rating in detecting student progress during the inpatient portion of an internal medicine clerkship. *Acad Med*, 76(10), s105-s107.
2. Kolotkin R, Crosby R, **Pendleton R**, et al (2003). Health-Related Quality of Life in Patients Seeking Gastric Bypass Surgery vs. Non-Treatment-Seeking Controls. *Obes Surg*, 13, 1-7.
3. **Pendleton R**, et al (2005). A double blind safety and efficacy study of the Oral Direct Thrombin Inhibitor, H376/95 versus standard therapy [Enoxaparin and Warfarin] in patients with Acute Symptomatic Deep venous thrombosis with or without Pulmonary Embolism. *JAMA*, 293, 681-689.
4. Stinnett JM, **Pendleton R**, Skordos L, Wheeler M, Rodgers GM (2005). Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. *Am J Hematol*, 78(3), 167-72.
5. Adams TD, Avelar E, Cloward T, Crosby RD, Farney RJ, Gress R, Halverson RC, Hopkins PN, Kolotkin RL, Lamonte MJ, Litwin S, Nuttall RT, **Pendleton R**, Rosamond W, Simper SC, Smith SC, Strong M, Walker JM, Wiebke G, Yanowitz FG, Hunt SC (2005). Design and rationale of the Utah obesity study. A study to assess morbidity following gastric bypass surgery. *Contemp Clin Trials*, 26(5), 534-51.
6. Creekmore F, **Pendleton RC**, et al (2006). The Incidence and Economic Implications of Heparin Induced Thrombocytopenia when Preventing Venous Thrombosis in Medical Patients. *Pharmacotherapy*. 26(10): 1438-45.
7. Avelar E, Cloward TV, Walker JM, Farney RJ, Strong M, **Pendleton RC**, Segerson N, Adams TD, Gress RE, Hunt SC, Litwin SE (2007). Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. *Hypertension*, 49(1), 34-9.
8. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JE, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, FitzGerald G, Anderson Jr FA, and the IMPROVE Investigators (2007). Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism. Prepublished online June 15, 2007. *Chest*.
9. **Pendleton RC**, Rondina MT, Wheeler M, Rodgers GM (2009). The effects of multifaceted intervention to improve venous thromboembolism prophylaxis are sustained over time. *Open Gen Intern Med J*, 3, 20-24.
10. Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, **Pendleton RC**, McLaren GD, Elliott CG, Stevens SM, Patton WF, Dabbagh O, Paterno MD, Catapane E, Li Z, Goldhaber SZ (2009). Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. *Circulation*, 119(16), 2196-201.
11. Vinik R, Jones RE, **Pendleton RC**, Ku SY (2009). Safety and efficacy of an insulin infusion protocol designed for the non-intensive care setting. *Endocr Pract*, 15(7), 682-8.
12. **Pendleton RC**, Wheeler M, Wanner N, Strong MB, Vinik R, Peters CL (2010). A safe, effective, and easy to use warfarin initiation dosing nomogram for post-joint arthroplasty patients. *J Arthroplasty*, 25(1), 121-7.

13. Adams TD, **Pendleton RC**, Strong MB, Kolotkin RL, Walker JM, Litwin SE, Berjaoui WK, LaMonte MJ, Cloward TV, Avelar E, Owan TE, Nuttall RT, Gress RE, Crosby RD, Hopkins PN, Brinton EA, Rosamond WD, Wiebke GA, Yanowitz FG, Farney RJ, Halverson RC, Simper SC, Smith SC, Hunt SC (2010). Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese. *Obesity (Silver Spring)*, 18(1), 121-30.
14. Rondina MT, Wheeler M, Rodgers GM, Draper L, **Pendleton RC** (2010). Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. *Thromb Res*, 125(3), 220-3.
15. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, **Pendleton RC**, Berg RL, Deloukas P, Gage BF (2010). Integration of genetic, clinical, and INR data to refine warfarin. *Clin Pharmacol Ther*, 87(5), 572-8.
16. McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, **Pendleton RC** (2010). Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. *Ther Drug Monit*, 32(3), 338-45.
17. Owan T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, Gallagher J, Williams Z, Preece K, Gundersen N, Strong MB, **Pendleton RC**, Segerson N, Cloward TV, Walker JM, Farney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE (2011). Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. *J Am Coll Cardiol*, 57(6), 732-9.
18. Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O'Neil BJ, Thompson JR, Hiestand B, Briese BA, **Pendleton RC**, Miller CD, Kline JA (2011). Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). *J Am Coll Cardiol*, 57(6), 700-6.
19. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, **Pendleton RC**, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF (2011). Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. *Pharmacogenomics J*.
20. Rondina MT, Wanner N, **Pendleton RC**, Kraiss LW, Vinik R, Zimmerman GA, Heilbrun M, Hoffman JM, Morton KA (2011). A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. *Thromb Res*.
21. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, **Pendleton RC**, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF (2012). Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. *Thromb Haemost*, 107(2), 232-40.

22. Freeman AL, **Pendleton RC** (2012). ACP Journal Club. Review: VTE prophylaxis in nonsurgical inpatients reduces PE but not death, and increases major bleeding. *Ann Intern Med*, 156(4), JC2-05.
23. Freeman A, Horner T, **Pendleton RC**, Rondina MT (2012). Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. *Am J Hematol*, 87(7), 740-3.
24. Borgman MP, **Pendleton RC**, McMillin GA, Reynolds KK, Vazquez S, Freeman A, Wilson A, Valdes R Jr, Linder MW (2012). Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. *Thromb Haemost*, 108(3), 561-9.
25. Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, **Pendleton RC**, Strong MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC (2012). Health benefits of gastric bypass surgery after 6 years. *JAMA*, 308(11), 1122-31.
26. Rondina MT, Lam UT, **Pendleton RC**, Kraiss LW, Wanner N, Zimmerman GA, Hoffman JM, Hanrahan C, Boucher K, Christian PE, Butterfield RI, Morton KA (2012). 18F-FDG PET in the Evaluation of Acuity of Deep Vein Thrombosis. *Clin Nucl Med*, 37(12), 1139-45.
27. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, **Pendleton RC**, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med*, 369(24), 2283-93.
28. Kawamoto K1, Martin CJ1, Williams K1, Tu MC1, Park CG1, Hunter C1, Staes CJ1, Bray BE1, Deshmukh VG1, Holbrook RA1, Morris SJ1, Feddersen MB1, Sletta A1, Turnbull J1, Mulvihill SJ1, Crabtree GL1, Entwistle DE1, McKenna QL1, Strong MB1, **Pendleton RC1**, Lee VS1. Value Driven Outcomes (VDO): a pragmatic, modular, and extensible software framework for understanding and improving healthcare costs and outcomes. *J Am Med Inform Assoc* (2015) Jan 22(1): 223-235.
29. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE Incidence and Risk Factors in Patients With Severe Sepsis. *Chest*. (2015) 148(5):1224-30.
30. Shih L, Kaplan D, Kraiss LW, Casper TC, **Pendleton RC**, Peters CL, Supiamo MA, Simmerman, GA, Weyrich AS, and Rondina MT. Platelet-Monocyte Aggregates and C-Reactive Protein are associated with VTE in Older Surgical Patients. *Sci Rep* (2016) Jun 7(6)
31. Pelt CE, Anderson MB, **Pendleton RC**, Foulks M, Peters CL, and Gilliland JM. Improving value in primary total arthroplasty care pathways: changes in inpatient physical therapy staffing. *Arthroplasty Today* (2016).
32. Vivian S. Lee, MD, PhD, MBA¹; Kensaku Kawamoto, MD, PhD, MHS¹; Rachel Hess, MD, MS¹; Charlton Park, MBA, MHSM¹; Jeffrey Young, MS¹; Cheri Hunter, BS¹; Steven Johnson, LSMBB, MBA¹; Sandi Gulbransen, BSIE¹; Christopher E. Pelt, MD¹; Devin J. Horton, MD¹; Kencee Graves, MD¹; Tom H. Greene, PhD¹; Yoshimi Anzai, MD, MPH¹; **Robert C. Pendleton, MD¹** Implementation of a value Driven Outcomes Program to Identify High Variability in Clinical Costs

and Outcomes and Association with Reduced Cost and Improved Quality. *JAMA* (2016) 316(10): 1061

34.

Gage BF, Bass AR...**Pendleton RC**...Roman VD, & Eby CS. Effect of Genotype-guided warfarin dosing on clinical events and anticoagulation control among patient undergoing hip or knee

35. arthroplasty. *JAMA* (2017); 318(12):1115-1124.

Vedantham S, Goldhaber SZ, et. al for the **ATTRACT investigators**. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. *N Engl J Med* (2017); 377: 2240-2252.

36.

MacLean C, Kerr E, Qaseem A, for the **APC Performance measurement committee**. Time out-charting a path for improving performance measurement. *N Engl J Med* (2018); DOI:

37. 10.1056/NEJMp1802595

Gage BF...**Pendleton RC**...Eby CS. Effect of Low Intensity vs Standard Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. *JAMA* (2019); 322 (9): 834-842.

Anzai Y, Delis K, **Pendleton RC**. Price Transparency in Radiology: A Model for the Future. *J Am Coll Radiol* (2020); 17 (Pt 1 B): 194-199.

NON PEER-REVIEWED JOURNAL ARTICLES

1. Adams TD, Heath EM, Lamonte MJ, Gress RE, **Pendleton RC**, Strong MB, Hunt SC (2007). The relationship between body mass index and percent body fat in the severely obese. *Diabetes Obes Metab*, 9(4), 498-505.

2.

Pendleton, RC. We won't get value-based healthcare until we agree on what Value means. *Harvard Business Review* (2018). https://hbr.org/2018/02/we-wont-get-value-based-health-care-until-we-agree-on-what-value-means?utm_source=twitter&utm_medium=social&utm_campaign=hbr (Accessed February 27, 2018)

REVIEW ARTICLES

1. **Pendleton R**, Wheeler M, Rodgers G (2005). Venous thromboembolism prevention in the acutely ill medical patient: a review of the literature and focus on special patient populations. [Review]. *Am J Hematol*, 79(3), 229-37.

2. **Pendleton R** (2006). Issues in Coagulation: A practical approach to periprocedural anticoagulation. [Review]. *Audio-Digest General Surgery*, 53(15).

3. Rondina M, **Pendleton R**, Wheeler M, Rodgers G (2007). VTE Treatment in Special Patient Populations. *Thromb Res*, 119, 391-402.

4. **Pendleton RC** (2007). Blood Issues: Anticoagulation Management of Special Populations. [Review]. *Audio-Digest General Surgery*, 54(3).

5. **Pendleton RC** (2009 May). Anticoagulants and Blood: An update on DVT/PE prophylaxis: SCIP and more. [Review]. *Audio-Digest General Surgery*, 56(10).

6. **Pendleton RC** (2009 May). Anticoagulants and Blood: New anticoagulants on the horizon: Is a change upon us? [Review]. *Audio-Digest General Surgery*, 56(10).

7. Vinik R, Wanner N, **Pendleton RC** (2009). Periprocedural antithrombotic management: a review of the literature and practical approach for the hospitalist physician. [Review]. *J Hosp Med*, 4(9), 551-9.
8. Rondina MT, Walker A, **Pendleton RC** (2010). Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. *Hosp Pract (Minneap)*, 38(2), 19-28.
9. **Pendleton RC**, Rodgers GM, Hull RD (2010). Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia. [Review]. *Clin Chest Med*, 31(4), 691-706.
10. Freeman AL, **Pendleton RC**, Rondina MT (2010). Prevention of venous thromboembolism in obesity. [Review]. *Expert Rev Cardiovasc Ther*, 8(12), 1711-21.
11. Hughson J, Newman J, **Pendleton RC** (2011). Hip fracture management for the hospital-based clinician: a review of the evidence and best practices. [Review]. *Hosp Pract (Minneap)*, 39(1), 52-61.
12. McMillin GA, Vazquez SR, **Pendleton RC** (2011). Current challenges in personalizing warfarin therapy. [Review]. *Expert Rev Clin Pharmacol*, 4(3), 349-62.
13. Wilcox R, **Pendleton RC**, Smock KJ, Rodgers GM (2011). Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. [Review]. *Hosp Pract (Minneap)*, 39(3), 23-34.
13. McMillin G, Vazquez S, **Pendleton RC** (2011 May). The Promise of Individualized Warfarin Therapy. *Expert Opin Pharmacother*, 4(3), 349-362.
14. **Pendleton RC**, Freeman AL (2011 July). Venous Thromboembolism: Prophylaxis in Medical Patients and Approach to Acute Treatment. *Hosp Physician*, 14(3).
15. Sehdev A, Wanner N, **Pendleton RC** (2012). Statins for the prevention of venous thromboembolism? a narrative review. [Review]. *Hosp Pract (Minneap)*, 40(3), 13-8.

BOOK CHAPTERS

1. Pendleton RC and Rodgers GM (2013). Thrombosis and Anti-Thrombotic Therapy. In *Wintrobe's Clinical Hematology* (Thirteenth edition). Lippincott, Williams, and Wilkins.

OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)

Case Reports

1. **Pendleton R**, Wheeler MM, Rodgers GM (2006). Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome. *Ann Pharmacother*, 40, 972-6.
2. Rondina MT, Raphael K, **Pendleton RC**, Sande MA (2006). Abdominal Aortitis due to Streptococcus pneumoniae and Enterobacter aerogenes: A Case Report and Review. *Journal of General Medicine*, 21(7), 796.
3. **Pendleton RC**, Rodgers GM (2006). An unusual case in the diagnosis and management of acute pulmonary embolism. *Am J Med*, 119(8), 651-653.
4. Vazquez SR, Rondina MT, **Pendleton RC** (2008). Azathioprine-induced warfarin resistance. *Ann Pharmacother*, 42(7), 1118-23.

5. Graves KK, Green LS, **Pendleton RC** (2010). Pulmonary embolism with unexpected echocardiogram findings. *Hosp Pract (Minneap)*, 38(1), 84-8.

Editorials

1. **Pendleton RC** (July 2009). Probability Assessment Key to PE. *Hospitalist News*, 2(7), 3.
2. **Pendleton RC** (May 2010). No Pay Rule for Catheter-associated UTIs - Focus Should Remain on Quality of Care. *Hospitalist News*.
3. Freeman AL, **Pendleton RC** (2012). ACP Journal Club. Review: VTE prophylaxis in nonsurgical inpatients reduces PE but not death, and increases major bleeding. *Ann Intern Med*, JC2-05, 156(4).
4. **Pendleton RC** (Dec 2012). EHR is best tool against ADE's (commentary on "many patients receive excessive acetaminophen"). *Hospitalist News*, 5(12):6.
5. **Pendleton RC** (March 2013). Systemness: The controversy over measuring patient experience. *Hospitalist News*.
6. **Pendleton RC** (April 2013). Systemness: The Dollars and Sense of Coding and Documentation. *Hospitalist News*.
7. **Pendleton RC** (July 2013). Systemness: How Safe is your hospital? Measuring patient safety is not so straightforward. *Hospitalist News*.
8. **Pendleton RC** (Sept 2013). Systemness: Process improvement in healthcare. *Hospitalist News*.

Letters

1. **Pendleton R** (2005). Advantages of Hospitalism [Letter to the editor]. *Patient Care*, 9-10.
2. **Pendleton RC**, Vazquez S (2009). Vitamin K to correct over-anticoagulation [Letter to the editor]. *Ann Intern Med*, 151(6), 433-4; author reply 435.
3. Vinik R, **Pendleton RC**, Jones RE (2010). In response to: Safety and efficacy of continuous insulin infusion in noncritical care settings [Letter to the editor]. *J Hosp Med*, 5(6), E10.

Video/Film/CD/Web/Podcast

1. **Pendleton RC** (2010 May). Prevention of VTE: A National Healthcare Priority [Web]. Physician Improvement. Available: <http://vte.physicianimprovement.com/users/page/php?id=120>.
2. **Pendleton RC** (2011 February). Sound strategies for the prevention of venouse thromboembolism - Part 3 [Podcast]. ReachMD XM Radio.
3. **Pendleton RC**, Merli G (2012 December). Stroke Prevention in Atrial Fibrillation: Translating Clinical trial Results to Daily Practice [Web]. Available: https://hospitalpracticemed.com/enduring-online-CME/?utm_campaign=Enduring%20CME%20-%20UofU&utm_medium=email&utm_source=newsletter&utm_content=www.hospitalpracticemed.com.
4. Daniels C, Ransco M, and Pendleton RC. How Chief Value Officer's Lead HealthCare Transformation. Accelerate (2016). <https://accelerate.uofuhealth.utah.edu/connect/how-utah-chief-value-officers-lead-healthcare-transformation>
5. <https://accelerate.uofuhealth.utah.edu/connect/how-utah-chief-value-officers-lead-healthcare-transformation>

- Pendleton RC. Revolution Comes to Health Care. Accelerate (2016).
6. <https://accelerate.uofuhealth.utah.edu/connect/revolution-comes-to-healthcare>
- Pendleton RC. The Elephant, The Rider, and the Path to Change in Healthcare. Accelerate (2017).
7. <https://accelerate.uofuhealth.utah.edu/connect/bob-pendleton-on-the-elephant-the-rider-and-change-in-health-care>
8. Pendleton RC. Candi's Story: When Health Care's Callings Hit Home. Accelerate (2017).
<https://accelerate.uofuhealth.utah.edu/connect/bob-pendleton-shares-candys-story-when-health-cares-failings-hit-home>
9. Pendleton RC. Three Steps From Harm. Accelerate (2017)
<https://accelerate.uofuhealth.utah.edu/connect/safe-systems-safe-patients>
10. Pendleton RC. The Hard Work of Health Care Certainty. Accelerate (2018).
<https://accelerate.uofuhealth.utah.edu/connect/bob-pendleton-the-hard-work-of-health-care-certainty>
11. Pendleton RC. Don't Let Metrics Undermine your Purpose. Accelerate (2019).
<https://accelerate.uofuhealth.utah.edu/connect/don-t-let-metrics-undermine-your-purpose>
12. Pendleton RC. Three Challenges for the Next Decade of Health Care. Accelerate (2019)
<https://accelerate.uofuhealth.utah.edu/connect/these-three-things>
- Graves K & Pendleton RC. Vision, Guard Rails, and Empowerment: Working in A Team of Teams
13 Culture. Accelerate (2020)
<https://accelerate.uofuhealth.utah.edu/connect/vision-guardrails-and-empowerment-working-in-a-team-of-teams-culture>
- Pendleton RC. Seven Principles of a Value Management System. Accelerate (2020).
<https://accelerate.uofuhealth.utah.edu/connect/7-principles-of-value-management-university-of-utah-health>